SLS Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Benzinga - Mentions: TEVA EW LLY MDT ...

10 Health Care Stocks With Whale Alerts In Today's Session

14 days ago - By: Benzinga - Mentions: PZZA

Papa John's Is Not First: Here Are 3 Other Stocks Rocked By Market-Moving Fake News

a month ago - By: Stocktwits - Mentions: IWO URTY

Why Is SELLAS Life Sciences Stock Falling Today?

a month ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

a month ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum

a month ago - By: Stocktwits

Sellas Life Sciences Stock Jumps Over 7% Premarket: Buzz Builds Ahead Of Weekend Cancer Drug Presentation In Berlin

a month ago - By: Stocktwits - Mentions: IWMW VTWG

SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment

a month ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025

2 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update

2 months ago - By: Stocktwits - Mentions: IWMW VTWG

Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants

3 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

3 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

4 months ago - By: Zacks Investment Research

SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

4 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study

5 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

5 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

6 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

6 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

6 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

6 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

7 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

7 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

7 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

8 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

8 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

9 months ago - By: SELLAS Life Sciences Group, Inc.

SELLAS LIFE SCIENCES GROUP I (SLS) Stock News

SLS Latest News, Press Relases and Analysis

10 Health Care Stocks With Whale Alerts In Today's Session

Papa John's Is Not First: Here Are 3 Other Stocks Rocked By Market-Moving Fake News

Why Is SELLAS Life Sciences Stock Falling Today?

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum

Sellas Life Sciences Stock Jumps Over 7% Premarket: Buzz Builds Ahead Of Weekend Cancer Drug Presentation In Berlin

SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment

SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025

SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update

Sellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing Warrants

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL